Sign in

CIK 0001398733

  • Non-accelerated filer
  • Smaller reporting company

Aquestive Therapeutics, Inc.

Sign in to watch
Ticker
AQST
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
208623253
Phone
+1 908-941-1900
Business address
184 LIBERTY CORNER ROAD, SUITE 305, WARREN, NJ
Former names
MonoSol Rx, Inc.
  1. 4 Open-market sale Chief People Officer sold 29,814 shares at $4.17 ($124,414)
  2. 4 Open-market sale President and CEO sold 180,677 shares at $4.17 ($753,965)
  3. 4 Open-market sale Chief Legal Officer sold 40,102 shares at $4.17 ($167,346)
  4. 4 Open-market sale SVP, Regulatory Affairs sold 25,311 shares at $4.17 ($105,623)
  5. 4 Open-market sale Chief Financial Officer sold 58,254 shares at $4.17 ($243,094)
  6. 4 Open-market sale Chief Commercial Officer sold 15,741 shares at $4.17 ($65,687)
  7. 4 Open-market sale Chief Operating Officer sold 45,791 shares at $4.17 ($191,086)
  8. 4 Grant or award Chief Development Officer acquired 50,000 shares (grant or award)
  9. 4 Grant or award Chief Medical Officer acquired 75,000 shares (grant or award)
  10. 3 Insider Initial Statement of Ownership
  11. 4 Grant or award Chief People Officer acquired 20,000 shares (grant or award)
  12. 4 Shares withheld for taxes SVP, Regulatory Affairs gave up 2,083 shares (to pay taxes)
  13. 4 Grant or award Chief Development Officer acquired 50,000 shares (grant or award)
  14. 3 Insider Initial Statement of Ownership
  15. 4 Planned sale Chief Operating Officer sold 67,575 shares at $7.01 ($473,701)
  16. 4 Planned sale Chief Medical Officer sold 20,272 shares at $7.00 ($141,904)
  17. 4 Planned sale See Remarks sold 10,000 shares at $7.00 ($70,000)
  18. 4 Planned sale President and CEO sold 91,343 shares at $6.03 ($551,191)
  19. 4 Planned sale See Remarks sold 10,000 shares at $6.30 ($63,000)
  20. 4 Planned sale President and CEO sold 400 shares at $6.00 ($2,400)

Page 3 of 17 · 326 filings